Daiichi Sankyo Company, Limited (TYO:4568)
Japan
· Delayed Price · Currency is JPY 3,547.00
-60.00 (-1.66%)
May 9, 2025, 3:30 PM JST
Daiichi Sankyo Company Revenue
In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T JPY with 17.77% growth. Daiichi Sankyo Company had revenue of 518.69B in the quarter ending March 31, 2025, with 21.07% growth.
Revenue
1,886.26B
Revenue Growth
+17.77%
P/S Ratio
3.51
Revenue / Employee
100.73M
Employees
18,726
Market Cap
6,621.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1,886.26B | 284.57B | 17.77% |
| Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
| Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
| Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Takeda Pharmaceutical Company | 4,579.02B |
| HOYA Corporation | 869.37B |
| Terumo | 1,011.15B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Olympus | 993.33B |
| Shionogi & | 456.87B |
Daiichi Sankyo Company News
- 2 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 - Benzinga
- 2 days ago - ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial - Benzinga
- 11 days ago - Approaching the business with a 'patient-centric mindset': Daiichi Sankyo CEO - CNBC
- 13 days ago - Daiichi Sankyo Company, Limited (DSKYF) FY2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Daiichi Sankyo rises on share buyback plan - Seeking Alpha
- 14 days ago - Daiichi Sankyo repors FY results - Seeking Alpha
- 18 days ago - ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 4 weeks ago - Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha